Recent Updates
Recently added Catalysts
AQST Positive Sentiment Score: 70/100

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

Key Takeaway: Aquestive Therapeutics, Inc. will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th. At the conference, the management team will participate in a fireside chat at 3:20 pm ET and hold investor meetings. A webcast of the discussion will be accessible for 30 days post-event. This participation underscores the company's commitment to innovation and investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aquestive Therapeutics is participating in the Oppenheimer Healthcare Conference, suggesting confidence in its growth.
  • The management team will engage with investors, demonstrating transparency and willingness to communicate about future plans.

Full Press Release Details

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th.
The Aquestive team will hold a fireside chat on February 13th at 3:20 pm ET and will host investor meetings.
A webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development activities and clinical trials, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, in its Quarterly Reports on Form 10-Q, and in its Current Reports on Form 8-K filed with the Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Stephanie Carrington

Frequently Asked Questions

When will Aquestive participate in the Oppenheimer Conference?

Aquestive will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th.

What time is the fireside chat at the conference?

The fireside chat is scheduled for 3:20 pm ET on February 13th.

Where can I watch the fireside chat webcast?

The webcast will be available on the 'Events and Presentation' page of the Investors section.

How long will the webcast replay be available?

A replay of the webcast will be accessible for 30 days following the event.

What does Aquestive Therapeutics focus on?

Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies.

Last updated: Jan 30, 2024